N
Neumora Therapeutics, Inc. (NMRA)
NMS – Real Time Price. Currency in USD
1.64
+0.13 (8.61%)
At close: Jun 26, 2026, 4:00 PM EDT
1.60
-0.04 (-2.44%)
After-hours: Jun 26, 2026, 7:11 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.64
+0.13 (8.61%)
At close: Jun 26, 2026, 4:00 PM EDT
1.60
-0.04 (-2.44%)
After-hours: Jun 26, 2026, 7:11 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $147.1M significantly exceed its total debt $53.4M, ensuring strong financial flexibility
Total current assets $153.4M exceed Total current liabilities $30.1M, highlighting excellent liquidity
Debt-to-equity ratio (0.8) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-28.5x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$46.4M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 5.09 | 6.05 | 10 | |
| Quick ratio | 5.09 | 5.63 | 10 | |
| Debt to Equity | 0.76 | 0.30 | 7.0 | |
| Debt to Assets | 0.35 | 1.04 | 6.0 | |
| Interest coverage | -28.51 | -16.91 | 1.0 | |
| Weighted average score | 6.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -3M | -668K | -631K | -208K | -59K |
| Operating Income | -123M | -188M | -263M | -236M | -218M |
| Net Income | -131M | -236M | -244M | -237M | -222M |
| EBITDA | -120M | -188M | -263M | -236M | -218M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 27.72 | 5.5 |
| Next quarter | N/A | 41.06 | 5.5 |
| Current year | N/A | 36.94 | 5.5 |
| Next year | N/A | 15.7 | 5.0 |
| Weighted average score | 5.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 10.08 | 14.29 | 3.2 | 7.3 |
| Y/Y | 999 | 21.38 | 28.57 | 21.94 | 10 |
| 3y average | 999 | -26.9 | 31.54 | -22.11 | 5.5 |
| 5y average | 999 | -34.98 | N/A | -57.87 | 3.3 |
| Weighted average score | 6.5 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |